- Round ID
- FR-00240
- Stage
- Series B
- Round name
- Growth round (stage label ambiguous in sources; confirmed Series B in 2021)
- Amount
- $200M (2024, unicorn/growth round); $50M (Series B, Sept 2021)
Dated funding evidence
Flo Health
Series B · $200M (2024, unicorn/growth round); $50M (Series B, Sept 2021) · 2024-07-30
Reported round$200M (2024, unicorn/growth round); $50M (Series B, Sept 2021)Series B
- Disclosure date
- 2024-07-30
- Reported currency
- USD
- Companies House
- 12898410
- Evidence sources
- 3
Company
Flo HealthCH 128984102024-07-30Series B$200M (2024, unicorn/growth round); $50M (Series B, Sept 2021)
Resolved investor records
No named investor resolved to an exact canonical investor record.
3 additional source-listed names are retained in the record fields below but not linked without an exact canonical match.
Investor links inherit this round’s named source and date. Resolved links use an exact canonical investor name; unresolved names remain unlinked.
Record fields
What the source states
Amounts, currency, stage and investor names are preserved as reported. No FX conversion, valuation inference or current-holding claim is added.
- Lead investors
- General Atlantic (2024 round)
- Other investors
- VNV Global (Series B, 2021), Target Global (Series B, 2021)
- Source layers
- VC research snapshot, Live Chris T D1
- Snapshot
- 2026-08-15
Named evidence
Source trail
This page is published only when the record has a resolved company, disclosure date, round stage and at least one retained source URL.